WO2021223751A1 - 抗肿瘤化合物的合成方法及其中间体 - Google Patents
抗肿瘤化合物的合成方法及其中间体 Download PDFInfo
- Publication number
- WO2021223751A1 WO2021223751A1 PCT/CN2021/092315 CN2021092315W WO2021223751A1 WO 2021223751 A1 WO2021223751 A1 WO 2021223751A1 CN 2021092315 W CN2021092315 W CN 2021092315W WO 2021223751 A1 WO2021223751 A1 WO 2021223751A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- reaction
- hours
- acid
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 330
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 27
- 238000001308 synthesis method Methods 0.000 title abstract description 10
- 238000006243 chemical reaction Methods 0.000 claims abstract description 163
- 238000000034 method Methods 0.000 claims abstract description 52
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 137
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 108
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 78
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 72
- 239000003960 organic solvent Substances 0.000 claims description 65
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 63
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 60
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 56
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 52
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 47
- 238000010992 reflux Methods 0.000 claims description 46
- 230000009471 action Effects 0.000 claims description 40
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 36
- 239000002585 base Substances 0.000 claims description 33
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 30
- 239000003054 catalyst Substances 0.000 claims description 30
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 30
- 239000002904 solvent Substances 0.000 claims description 29
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims description 28
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 27
- 125000003118 aryl group Chemical group 0.000 claims description 27
- 238000010534 nucleophilic substitution reaction Methods 0.000 claims description 26
- 230000002194 synthesizing effect Effects 0.000 claims description 26
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 25
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 23
- 239000002253 acid Substances 0.000 claims description 23
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 23
- 230000035484 reaction time Effects 0.000 claims description 23
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 23
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 21
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 21
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 claims description 20
- -1 EOMCl Chemical compound 0.000 claims description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 20
- 239000003153 chemical reaction reagent Substances 0.000 claims description 20
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 18
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 claims description 17
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 16
- IAAASXBHFUJLHW-UHFFFAOYSA-N 3,5-diethyl-1-phenyl-2-propyl-2h-pyridine Chemical compound C1=C(CC)C=C(CC)C(CCC)N1C1=CC=CC=C1 IAAASXBHFUJLHW-UHFFFAOYSA-N 0.000 claims description 15
- 229910052736 halogen Inorganic materials 0.000 claims description 15
- 150000002367 halogens Chemical class 0.000 claims description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- 125000006239 protecting group Chemical group 0.000 claims description 15
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 14
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 14
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 13
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 claims description 12
- 229910003446 platinum oxide Inorganic materials 0.000 claims description 12
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 claims description 12
- 238000007792 addition Methods 0.000 claims description 11
- GIGRWGTZFONRKA-UHFFFAOYSA-N 1-(bromomethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CBr)C=C1 GIGRWGTZFONRKA-UHFFFAOYSA-N 0.000 claims description 10
- IRXSLJNXXZKURP-UHFFFAOYSA-N fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 claims description 10
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 10
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 10
- 238000006722 reduction reaction Methods 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 9
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 9
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 8
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 8
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 8
- 235000019253 formic acid Nutrition 0.000 claims description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 8
- 239000012312 sodium hydride Substances 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 125000003277 amino group Chemical group 0.000 claims description 7
- 235000019270 ammonium chloride Nutrition 0.000 claims description 7
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 7
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 7
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 7
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 claims description 7
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 claims description 7
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 claims description 6
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 claims description 6
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 claims description 6
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 5
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 239000000460 chlorine Substances 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 229910017604 nitric acid Inorganic materials 0.000 claims description 5
- 229910052763 palladium Inorganic materials 0.000 claims description 5
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 5
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 claims description 4
- 238000006396 nitration reaction Methods 0.000 claims description 4
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 claims description 4
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 3
- QQIRAVWVGBTHMJ-UHFFFAOYSA-N [dimethyl-(trimethylsilylamino)silyl]methane;lithium Chemical compound [Li].C[Si](C)(C)N[Si](C)(C)C QQIRAVWVGBTHMJ-UHFFFAOYSA-N 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 14
- 238000005516 engineering process Methods 0.000 abstract description 3
- 238000009776 industrial production Methods 0.000 abstract description 3
- 239000006227 byproduct Substances 0.000 abstract description 2
- 238000001953 recrystallisation Methods 0.000 abstract description 2
- 239000002699 waste material Substances 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 36
- 230000015572 biosynthetic process Effects 0.000 description 30
- 238000003756 stirring Methods 0.000 description 28
- 238000003786 synthesis reaction Methods 0.000 description 27
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 24
- 239000012065 filter cake Substances 0.000 description 24
- 239000007787 solid Substances 0.000 description 23
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 14
- 238000004128 high performance liquid chromatography Methods 0.000 description 14
- 239000000706 filtrate Substances 0.000 description 13
- 239000000543 intermediate Substances 0.000 description 13
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 8
- 238000004809 thin layer chromatography Methods 0.000 description 8
- 0 Cc([n](*)nc1N(C(c2c3cccc2)=O)C3=O)c1[N+]([O-])=O Chemical compound Cc([n](*)nc1N(C(c2c3cccc2)=O)C3=O)c1[N+]([O-])=O 0.000 description 7
- 239000012141 concentrate Substances 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 239000005457 ice water Substances 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 108091008605 VEGF receptors Proteins 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000000967 suction filtration Methods 0.000 description 4
- QYKQQHCKNQLQSM-UHFFFAOYSA-N (6-bromopyridin-3-yl)-(2-chlorophenyl)methanol Chemical compound OC(c1ccc(Br)nc1)c1ccccc1Cl QYKQQHCKNQLQSM-UHFFFAOYSA-N 0.000 description 3
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 3
- LMWRUVZWLBOLRD-UHFFFAOYSA-M [Cl-].[Mg+]C1=CC=CC=C1Cl Chemical compound [Cl-].[Mg+]C1=CC=CC=C1Cl LMWRUVZWLBOLRD-UHFFFAOYSA-M 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 238000011403 purification operation Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- HPPDPZCBIJDRIY-UHFFFAOYSA-N (6-bromopyridin-3-yl)-(2-chlorophenyl)methanone Chemical compound Clc1ccccc1C(=O)c1ccc(Br)nc1 HPPDPZCBIJDRIY-UHFFFAOYSA-N 0.000 description 2
- FPYUJUBAXZAQNL-UHFFFAOYSA-N 2-chlorobenzaldehyde Chemical compound ClC1=CC=CC=C1C=O FPYUJUBAXZAQNL-UHFFFAOYSA-N 0.000 description 2
- UHLHNLZULRWKJR-UHFFFAOYSA-N 4,6-dichloropyridine-3-carbonyl chloride Chemical compound ClC(=O)C1=CN=C(Cl)C=C1Cl UHLHNLZULRWKJR-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000003989 Aurora kinases Human genes 0.000 description 2
- 108090000433 Aurora kinases Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229940127204 compound 29 Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- LZKLAOYSENRNKR-LNTINUHCSA-N iron;(z)-4-oxoniumylidenepent-2-en-2-olate Chemical compound [Fe].C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O LZKLAOYSENRNKR-LNTINUHCSA-N 0.000 description 2
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 2
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- ZHAUYRZKZGHGSR-UHFFFAOYSA-N (2-chlorophenyl)-(4,6-dichloropyridin-3-yl)methanone Chemical compound O=C(C(C=CC=C1)=C1Cl)C(C=NC(Cl)=C1)=C1Cl ZHAUYRZKZGHGSR-UHFFFAOYSA-N 0.000 description 1
- FKRCCAOJXDNYGX-UHFFFAOYSA-N (6-bromo-4-iodopyridin-3-yl)-(2-chlorophenyl)methanone Chemical compound Clc1ccccc1C(=O)c1cnc(Br)cc1I FKRCCAOJXDNYGX-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- RVWUHFFPEOKYLB-UHFFFAOYSA-N 2,2,6,6-tetramethyl-1-oxidopiperidin-1-ium Chemical compound CC1(C)CCCC(C)(C)[NH+]1[O-] RVWUHFFPEOKYLB-UHFFFAOYSA-N 0.000 description 1
- PZHIYZLLIBBPFK-UHFFFAOYSA-N 2,4-dichloro-5-(chloromethyl)pyridine Chemical compound ClCC1=CN=C(Cl)C=C1Cl PZHIYZLLIBBPFK-UHFFFAOYSA-N 0.000 description 1
- ZHXUWDPHUQHFOV-UHFFFAOYSA-N 2,5-dibromopyridine Chemical compound BrC1=CC=C(Br)N=C1 ZHXUWDPHUQHFOV-UHFFFAOYSA-N 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- PVQRYRIININRCP-UHFFFAOYSA-N 5-methyl-4-nitro-1-(oxan-2-yl)pyrazol-3-amine Chemical compound CC(N(C1OCCCC1)N=C1N)=C1[N+]([O-])=O PVQRYRIININRCP-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- STWJBXKXZUGDDR-UHFFFAOYSA-N CC(C(C1N)[N+]([O-])=O)NN1I Chemical compound CC(C(C1N)[N+]([O-])=O)NN1I STWJBXKXZUGDDR-UHFFFAOYSA-N 0.000 description 1
- CZOHOTWOZBADEO-UHFFFAOYSA-N CC(C1N=C(c2ccccc2Cl)c(cnc(N2CCOCC2)c2)c2NC1N)N(I)I Chemical compound CC(C1N=C(c2ccccc2Cl)c(cnc(N2CCOCC2)c2)c2NC1N)N(I)I CZOHOTWOZBADEO-UHFFFAOYSA-N 0.000 description 1
- XVVFSTTWZSHGJT-UHFFFAOYSA-N CC(N(C(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)N=C1NC(C=C(N2CCOCC2)N=C2)=C2C(C(C=CC=C2)=C2Cl)=O)=C1[N+]([O-])=O Chemical compound CC(N(C(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)N=C1NC(C=C(N2CCOCC2)N=C2)=C2C(C(C=CC=C2)=C2Cl)=O)=C1[N+]([O-])=O XVVFSTTWZSHGJT-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- JRKZNZSSEUGDQY-UHFFFAOYSA-N Cc([nH]nc1N(C(c2ccccc22)=O)C2=O)c1[N+]([O-])=O Chemical compound Cc([nH]nc1N(C(c2ccccc22)=O)C2=O)c1[N+]([O-])=O JRKZNZSSEUGDQY-UHFFFAOYSA-N 0.000 description 1
- UYUJGEQBSXWBAQ-UHFFFAOYSA-N Cc1cc(N(C(c2c3cccc2)=O)C3=O)n[nH]1 Chemical compound Cc1cc(N(C(c2c3cccc2)=O)C3=O)n[nH]1 UYUJGEQBSXWBAQ-UHFFFAOYSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical compound F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- DRDRZHJTTDSOPK-UHFFFAOYSA-N bis(2-chlorophenyl)methanone Chemical compound ClC1=CC=CC=C1C(=O)C1=CC=CC=C1Cl DRDRZHJTTDSOPK-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- FCYRSDMGOLYDHL-UHFFFAOYSA-N chloromethoxyethane Chemical compound CCOCCl FCYRSDMGOLYDHL-UHFFFAOYSA-N 0.000 description 1
- 229940061627 chloromethyl methyl ether Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 125000005594 diketone group Chemical group 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BNHFWQQYLUPDOG-UHFFFAOYSA-N lithium;1,2,2,3-tetramethylpiperidine Chemical compound [Li].CC1CCCN(C)C1(C)C BNHFWQQYLUPDOG-UHFFFAOYSA-N 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000005489 p-toluenesulfonic acid group Chemical group 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- ZCEORUDBPJWJEK-UHFFFAOYSA-N propan-2-ol;2,2,2-trifluoroacetic acid Chemical compound CC(C)O.OC(=O)C(F)(F)F ZCEORUDBPJWJEK-UHFFFAOYSA-N 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the invention belongs to the technical field of medicine, and specifically relates to a method for synthesizing an anti-tumor compound and its intermediates.
- VEGF/VEGFR vascular endothelial growth factor/vascular endothelial growth factor receptor
- Patent WO2018108079A1 discloses a series of compounds that can inhibit, regulate and/or regulate the activity of one or more protein kinases such as Aurora kinase and VEGFR kinase, by inhibiting the growth and migration of tumors, reversing the tumor microenvironment, and exerting tumor immune effects and anti-tumor effects. Tumor efficacy.
- the patent records the synthesis method of compound 29. Through further research, it is found that the synthesis process still needs to be optimized to obtain a simpler process, higher yield, higher purity, lower cost, and a synthetic method suitable for industrial production. .
- the present invention provides the following technical solutions 1-15:
- X 1 and X 2 are each selected from halogen;
- P 1 is an amino protecting group, preferably, P 1 is selected from Boc, Cbz, Tos, Fmoc, PMB, MOM, EOM, tBu, Bn, Ac, SEM, Trt or THP, such as Boc, Cbz, Tos, Fmoc, PMB, Trt or THP;
- P 1 is connected to any N atom on the ring, preferably P 1 is connected to the N atom ortho to the methyl group on the ring.
- P 1 is an amino protecting group, preferably, P 1 is selected from Boc, Cbz, Tos, Fmoc, PMB, MOM, EOM, tBu, Bn, Ac, SEM, Trt or THP, such as Boc, Cbz, Tos, Fmoc , PMB, Trt or THP; P 1 is connected to any N atom on the ring, preferably P 1 is connected to the N atom ortho to the methyl group on the ring.
- P 1 is an amino protecting group, preferably, P 1 is selected from Boc, Cbz, Tos, Fmoc, PMB, MOM, EOM, tBu, Bn, Ac, SEM, Trt or THP, such as Boc, Cbz, Tos, Fmoc , PMB, Trt or THP; P 1 is connected to any N atom on the ring, preferably P 1 is connected to the N atom ortho to the methyl group on the ring.
- P 1 is an amino protecting group, preferably, P 1 is selected from Boc, Cbz, Tos, Fmoc, PMB, MOM, EOM, tBu, Bn, Ac, SEM, Trt or THP, such as Boc, Cbz, Tos, Fmoc , PMB, Trt or THP; P 1 is connected to any N atom on the ring, preferably P 1 is connected to the N atom ortho to the methyl group on the ring.
- X 1 and X 2 are each selected from halogen;
- P 1 is an amino protecting group, preferably P 1 is selected from Boc, Cbz, Tos, Fmoc, PMB, MOM, EOM, tBu, Bn, Ac, SEM, Trt or THP , Such as Boc, Cbz, Tos, Fmoc, PMB, Trt or THP;
- P 1 is connected to any N atom on the ring, preferably P 1 is connected to the N atom ortho to the methyl group on the ring.
- step (a) the organic solvent is selected from one or more of 2-methyltetrahydrofuran, acetonitrile, tetrahydrofuran and toluene;
- the base is selected from one of sodium hydride, sodium hydroxide, cesium carbonate, triethylene diamine, sodium tert-butoxide, potassium tert-butoxide, lithium bistrimethylsilylamide and sodium hexamethyldisilazide Species or several
- the reaction pressure is 0 to 10 MPa (gauge pressure), such as normal pressure;
- the reaction time is 1-96 hours, such as 17 hours; the reaction temperature can be the reflux temperature;
- the reaction time is 3-18 hours, for example, the reaction time is 3-8 hours;
- the reaction temperature is 40°C to 70°C,
- the reaction temperature is 40°C to 60°C;
- the reaction time is 8 hours to 16 hours, for example, 13 hours to 16 hours;
- the reaction temperature can be the reflux temperature;
- the ratio is:
- magnesium sulfate is added during the aromatic nucleophilic substitution reaction between the compound of formula 1 and the compound of formula 2M under the action of a base, and acetic acid is added during the continued aromatic nucleophilic substitution reaction with the compound of formula 3,
- the ratio is:
- Solvent: compound of formula 1: compound of formula 2M: compound of formula 3: base: magnesium sulfate: acetic acid 0.5-60L: 0.1-11 mole: 1 mole: 0.3-30 mole: 0.2-25 mole: 0.2-20 mole: 0.1- 15 moles, for example, 5.8L: 1.1 moles: 1 mole: 3 moles: 2.5 moles: 1.6 moles: 1.5 moles.
- step (b) the organic solvent is selected from one of methanol, ethanol, isopropanol, tetrahydrofuran, 2-methyltetrahydrofuran, acetic acid and acetonitrile One or more;
- the catalyst is selected from iron powder, platinum oxide, Pt/C, Pd(OH) 2 /C, Rh/C or Pd/C;
- the reaction time is 1-96 hours, such as 15-24 hours;
- the reaction pressure is 0 to 10 MPa (gauge pressure), such as normal pressure;
- the reaction temperature is the reflux temperature ;
- the ratio is:
- step (b) when the catalyst is iron powder: In step (b), an amount of 0.05-5 moles, such as 0.5 moles, of ammonium chloride is also added; the solvent is a mixed solvent of ethanol and tetrahydrofuran, for example, the volume ratio of ethanol to tetrahydrofuran is (6 to 10): 10;
- step (b) a small amount of water is added in step (b), for example, the volume ratio of water to tetrahydrofuran is (0.2 to 2):10.
- step (c) the acid is selected from one of trifluoroacetic acid, methanesulfonic acid, p-toluenesulfonic acid, formic acid, acetic acid and hydrochloric acid Or several;
- the organic solvent is selected from at least one of dichloromethane, methanol, ethanol and isopropanol;
- step (c) is specifically: the compound of formula 5M is reacted in isopropanol under reflux under the action of trifluoroacetic acid for 1 hour to 3 hours.
- step (d) the organic solvent is selected from one of toluene, dichloromethane, acetonitrile, tetrahydrofuran, methanol, ethanol and isopropanol Or several
- step (d) an acid is also added, and the acid is selected from at least one of formic acid, acetic acid, hydrochloric acid, methanesulfonic acid and trifluoroacetic acid;
- step (d) alcohol or phenol other than the solvent is added; the alcohol is selected from methanol and/or ethanol, and the phenol is selected from phenol and/or p-methoxyphenol;
- the amino protecting reagent is Boc 2 O, CbzCl, TosCl, FmocCl, PMBBr, MOMCl, EOMCl, tert-butanol, isobutylene, BnCl, acetic anhydride, SEMCl, TrtCl or DHP, such as Boc 2 O, CbzCl, TosCl, FmocCl, PMBBr, TrtCl or DHP; P 1 is selected from Boc, Cbz, Tos, Fmoc, PMB, MOM, EOM, tBu, Bn, Ac, SEM, Trt or THP, such as Boc, Cbz, Tos, Fmoc, PMB, Trt Or THP; P 1 is connected to any N atom on the ring, preferably P 1 is connected to the N atom ortho to the methyl group on the ring.
- step (ii) When the amino-protecting reagent is TrtCl, the reaction conditions of step (ii) are: under the action of a base, react at 60°C to 100°C for 1 hour to 48 hours;
- step (ii) When the amino group protecting reagent is DHP, the reaction conditions of step (ii) are: under the action of p-toluenesulfonic acid or pyridine p-toluenesulfonate, reflux reaction at 60°C to 100°C for 3 hours to 48 hours.
- the compound of formula 1-1 for example, 1 to 2 molar equivalents
- the compound of formula 1-2 for example, 1 to 2 molar equivalents
- a coupling reaction reaction time: 2-4 hours, Reaction temperature: at -70 to 60°C
- X 1 , X 2 and X 3 are each selected from halogen; preferably, X 1 , X 2 and X 3 are each selected from chlorine.
- X 1 and X 2 are each selected from halogen
- P 1 is selected from Trt or THP; P 1 is connected to any N atom on the ring, preferably P 1 is connected to the N atom ortho to the methyl group on the ring.
- P 1 is selected from Trt or THP; P 1 is connected to any N atom on the ring, preferably P 1 is connected to the N atom ortho to the methyl group on the ring;
- the formula 6M is a complex containing 1 molecule of trifluoroacetic acid and 1 molecule of isopropanol.
- the purpose of the present invention is to provide a method for synthesizing an anti-tumor compound of Formula 7, which includes the following steps:
- X 1 and X 2 are each selected from halogen; P 1 is an amino protecting group, and P 1 is selected from Boc, Cbz, Tos, Fmoc, PMB, MOM, EOM, tBu, Bn, Ac, SEM, Trt or THP, for example Boc, Cbz, Tos, Fmoc, PMB, Trt or THP.
- the organic solvent is selected from one or more of 2-methyltetrahydrofuran, acetonitrile, tetrahydrofuran, and toluene;
- the base is selected from sodium hydride, sodium hydroxide , Cesium carbonate, triethylenediamine, sodium tert-butoxide, potassium tert-butoxide, lithium bistrimethylsilylamide and sodium hexamethyldisilazide.
- the organic solvent is selected from one or more of methanol, ethanol, isopropanol, tetrahydrofuran, 2-methyltetrahydrofuran and acetonitrile;
- the catalyst is selected from iron powder , Platinum oxide, Pt/C or Pd/C.
- the acid is selected from one or more of trifluoroacetic acid, methanesulfonic acid, p-toluenesulfonic acid, formic acid, acetic acid and hydrochloric acid;
- the organic solvent is selected from At least one of methylene chloride, methanol, ethanol, and isopropanol.
- step (c) is specifically: the compound of formula 5 is reacted in isopropanol under reflux under the action of trifluoroacetic acid for 1 hour to 3 hours, such as 1.5 hours to 3 hours.
- the organic solvent is selected from one or more of toluene, dichloromethane, acetonitrile, tetrahydrofuran, methanol, ethanol and isopropanol;
- a catalyst is also added, and the catalyst is selected from at least one of formic acid, acetic acid, hydrochloric acid, methanesulfonic acid and trifluoroacetic acid;
- step (d) alcohol or phenol is also added; the alcohol is selected from methanol and/or ethanol, and the phenol is selected from phenol and/or p-methoxyphenol.
- it further includes the step of synthesizing the compound of formula 2:
- the amino protecting reagent is Boc 2 O, CbzCl, TosCl, FmocCl, PMBBr, MOMCl, EOMCl, tert-butanol, isobutylene, BnCl, acetic anhydride, SEMCl, TrtCl or DHP, such as Boc 2 O, CbzCl, TosCl, FmocCl, PMBBr, TrtCl or DHP; P 1 is selected from Boc, Cbz, Tos, Fmoc, PMB, MOM, EOM, tBu, Bn, Ac, SEM, Trt or THP, such as Boc, Cbz, Tos, Fmoc, PMB, Trt Or THP.
- the reaction conditions of step (ii) are: under the action of a base, the reaction is carried out at 60°C to 100°C for 1 hour to 48 hours;
- step (ii) When the amino group protecting reagent is DHP, the reaction conditions of step (ii) are: under the action of p-toluenesulfonic acid or pyridine p-toluenesulfonate, reflux reaction at 60°C to 100°C for 3 hours to 48 hours.
- it further includes the step of synthesizing the compound of formula 1:
- the compound of formula 1-1 is reacted with the compound of formula 1-2 to obtain the compound of formula 1;
- X 1 , X 2 and X 3 are each selected from halogen; preferably, X 1 , X 2 and X 3 are each selected from chlorine.
- the present invention also provides an intermediate for preparing the anti-tumor compound of Formula 7, which has the following structural formula:
- X 1 and X 2 are each selected from halogen
- P 1 is selected from Trt or THP;
- P 2 is selected from Trt or THP, and P 3 is not present; or P 3 is selected from Trt or THP, and P 2 is not present;
- PG 1 is acetyl or PG 1 -NH- is
- the present invention provides an intermediate for preparing an anti-tumor compound of Formula 7, which has the following structural formula:
- P 1 is selected from Trt or THP;
- the formula 6 is a complex containing 1 molecule of trifluoroacetic acid and 1 molecule of isopropanol.
- the present invention has the following beneficial effects:
- the present invention is different from the existing synthesis process that first deprotects and then forms a triple ring. It adopts a method of synthesizing the triple ring first and then deprotects it. It uses an intermediate (compound of formula 2) as a raw material and undergoes an aromatic nucleophilic process. After the substitution reaction and the reduction reaction, the compound of formula 5 is obtained, so that the compound of formula 5 can realize the process of forming a triple ring first and then deprotecting, thus avoiding the shortcomings of the existing technology. 1 A large amount of trifluorocarbon must be used in the first deprotection. The problem of waste water produced by acetic acid, 2reduction of stannous chloride into a ring after the formation of a triple ring, operability and complicated post-treatment problems, 3the overall process is complicated and needs to be achieved through a column.
- the synthetic method of the present invention has enhanced operability and simplified process.
- the synthesized compound of formula 7 can obtain higher purity without complicated recrystallization process, reduce the generation of three wastes, and is more suitable for large-scale industrial production. .
- Halogen refers to fluorine, chlorine, bromine, iodine, etc.
- Boc 2 O means: di-tert-butyl dicarbonate
- Boc means: tert-butoxycarbonyl
- CbzCl means: benzyl chloroformate
- TosCl means: p-toluenesulfonyl chloride
- Tos means: p-toluenesulfonyl
- FluorCl means: 9-fluorene methyl chloroformate
- Fmoc means: 9-fluorenylmethoxycarbonyl
- PMB means: p-methoxybenzyl
- MOMCl means: chloromethyl methyl ether
- MCM methoxymethyl
- EOMCl means: chloromethyl ethyl ether
- EOM means: ethoxymethyl
- Tu means: tert-butyl
- SEMCl means: 2-(trimethylsilyl)ethoxymethyl chloride
- TrtCl means: triphenylchloromethane
- Trt means: triphenylmethyl
- DHP means: 3,4-dihydro-2H-pyran
- THP means: 2-tetrahydropyranyl
- THF tetrahydrofuran
- MTBE means: methyl tert-butyl ether
- ACN means: acetonitrile
- TAA triethylamine
- TFA means: trifluoroacetic acid
- IPA means: isopropanol
- TEMPO means: 2,2,6,6-tetramethylpiperidine-1-oxide
- DCM dichloromethane
- TLC means: Thin Layer Chromatography
- HNMR Hydrogen Nuclear Magnetic Resonance Spectroscopy
- DMSO means: dimethyl sulfoxide
- HPLC means: high performance liquid chromatography
- PE means: petroleum ether
- EA means: ethyl acetate
- LC-MS means: liquid chromatography-mass spectrometry.
- the catalyst includes a substance capable of changing the reaction rate in a conventional sense, and also includes a substance that plays a role of redox or acid-base in the reaction.
- reaction is carried out under normal pressure.
- the reaction temperature refers to the highest temperature reached during the reaction. The entire process of the reaction or part of the process is carried out at the maximum temperature.
- the feed amount is the amount of the one-time feed
- the feeding amount is the sum of the feeding amount of the several times.
- the various materials mentioned in the ratio can be fed simultaneously or separately.
- the chemical structural formula represents the free base or free acid form of the compound represented by the formula, as well as the form of hydrate, solvate, acid salt, basic salt, and combinations thereof, such as the following formula A can include the free base form of formula A, and various complexes of formula A, for example, a complex containing 1 molecule of trifluoroacetic acid and 1 molecule of isopropanol (as shown in formula B below):
- the present invention provides a method for synthesizing an anti-tumor compound of Formula 7, which includes the following steps:
- X 1 and X 2 are each selected from halogen;
- P 1 is an amino protecting group, preferably P 1 is selected from Boc, Cbz, Tos, Fmoc, PMB, MOM, EOM, tBu, Bn, Ac, SEM, Trt or THP , Such as Boc, Cbz, Tos, Fmoc, PMB, Trt or THP;
- P 1 is connected to any N atom on the ring, preferably P 1 is connected to the N atom ortho to the methyl group on the ring.
- the compound of formula 2M includes the following compound of formula 2 and compound of formula 2m:
- the compound of formula 2M is compound of formula 2.
- the compounds of formula IM include the following compounds of formula I and compounds of formula Im:
- the compound of formula IM is a compound of formula I.
- the compound of formula 4M includes the following compound of formula 4 and compound of formula 4m:
- the compound of formula 4M is a compound of formula 4.
- the compound of formula 5M includes the following compound of formula 5 and compound of formula 5m:
- the compound of formula 5M is a compound of formula 5.
- the compound of formula 6M includes the following compound of formula 6 and compound of formula 6m:
- the compound of formula 6M is a compound of formula 6.
- P 1 is selected from Trt or THP.
- the method for synthesizing the compound of formula 4 is step (a): in an organic solvent, the compound of formula 1 and the compound of formula 2 undergo an aromatic nucleophilic substitution reaction under the action of a base to obtain a compound of formula I, a compound of formula IM Without separation, the aromatic nucleophilic substitution reaction continues with the compound of formula 3, for example, the aromatic nucleophilic substitution reaction continues with the compound of formula 3 under alkaline conditions to obtain the compound of formula 4.
- the product I after the reaction of the compound of formula 1 and the compound of formula 2 does not need to be separated, but directly reacts with the compound of formula 3, which simplifies the process and improves the yield.
- the organic solvent is selected from one or more of 2-methyltetrahydrofuran, acetonitrile, tetrahydrofuran and toluene.
- the organic solvent is selected from 2-methyltetrahydrofuran or acetonitrile.
- the base is selected from sodium hydride, sodium hydroxide, cesium carbonate, triethylene diamine, sodium tert-butoxide, potassium tert-butoxide, lithium bistrimethylsilylamide and One or more of sodium hexamethyldisilazane.
- the basic conditions described in step (a) may not add an additional base, and morpholine may be used as the base, or an additional alkaline reagent, such as sodium hydride, sodium hydroxide, cesium carbonate, three One or more of ethylene diamine, sodium tert-butoxide, potassium tert-butoxide, lithium bistrimethylsilylamide, and sodium hexamethyldisilazide.
- the base is sodium hydride and the solvent is 2-methyltetrahydrofuran.
- step (a) the conditions for the aromatic nucleophilic substitution reaction between the compound of formula 1 and the compound of formula 2 are: reacting at 40°C to 70°C for 3 hours to 18 hours; for example, at 40°C to 60°C. React at °C for 3 hours to 8 hours.
- the conditions for continuing the aromatic nucleophilic substitution reaction with the compound of formula 3 are: reflux reaction for 8 hours to 16 hours; for example, reflux reaction for 8 hours to 12 hours; or, for example, reflux reaction 13 hours to 16 hours.
- step (a) the molar ratio of the compound of formula 1, the compound of formula 2 and the compound of formula 3 is (1 to 1.2):1:3.
- magnesium sulfate, molecular sieve or activated carbon can also be added as a catalyst.
- magnesium sulfate is added as a catalyst, and the addition amount of magnesium sulfate is 0.2 to 3 molar equivalents of the compound of formula 2; for example, the addition amount of magnesium sulfate is 2 to 3 molar equivalents of the compound of formula 2; or, for example, the addition of magnesium sulfate The amount is 1 to 3 molar equivalents of the compound of formula 2.
- step (a) the compound of formula 4 is purified, and the purification operation can be carried out by a conventional method in the art.
- the present invention also provides another method for synthesizing the compound of formula 4, which includes the following steps:
- the compound of formula 1 and the compound of formula 2 undergo an aromatic nucleophilic substitution reaction under the action of a base to obtain a compound of formula I;
- X 1 and X 2 are each selected from halogen;
- P 1 is an amino protecting group, preferably P 1 is selected from Boc, Cbz, Tos, Fmoc, PMB, MOM, EOM, tBu, Bn, Ac, SEM, Trt or THP , Such as Boc, Cbz, Tos, Fmoc, PMB, Trt or THP.
- the organic solvent is selected from one or more of 2-methyltetrahydrofuran, acetonitrile, tetrahydrofuran and toluene.
- the base is selected from one of sodium hydride, sodium hydroxide, cesium carbonate, triethylene diamine, sodium tert-butoxide, potassium tert-butoxide, lithium bistrimethylsilylamide and sodium hexamethyldisilazidekind or several kinds.
- the synthesis steps and reaction conditions of the compound of formula 4m are as described in the synthesis method of the compound of formula 4 above, except that the compound of formula 2 is replaced with the compound of formula 2m, and the compound of formula I is replaced with the compound of formula Im.
- the method for synthesizing the compound of formula 5 is step (b): in an organic solvent, the compound of formula 4 is subjected to a reduction reaction under the action of a catalyst to obtain the compound of formula 5.
- the organic solvent is selected from one or more of methanol, ethanol, isopropanol, tetrahydrofuran, 2-methyltetrahydrofuran, acetic acid, and acetonitrile.
- the catalyst in step (b), is selected from iron powder, platinum oxide, Pt/C, Pd(OH) 2 /C, Rh/C, or Pd/C.
- the mass fraction of Pt/C and Rh/C is 5%; the mass fraction of Pd/C is 5% and 10%; the mass fraction of Pd(OH) 2 /C is 10% and 20%.
- the addition amount of iron powder is 10 to 18 molar equivalents of the compound of formula 4; for example, the addition amount of iron powder is 14 to 18 molar equivalents of the compound of formula 4.
- step (b) ammonium chloride is also added, and the addition amount of ammonium chloride is 0.4 to 0.6 molar equivalent of the compound of formula 4;
- the solvent is a mixed solvent of ethanol and tetrahydrofuran; for example, the volume ratio of ethanol to tetrahydrofuran is ( 6 to 10):10.
- a small amount of water is added in step (b), and the volume ratio of water to tetrahydrofuran is (0.2 to 0.5):10.
- the conditions for the reduction reaction to occur are: reflux reaction for 15 hours to 24 hours.
- the conditions for the reduction reaction are: in a hydrogen atmosphere (for example, under 0.5-0.8 MPa), the reaction is conducted at 35° C. to 80° C. for 20 to 70 hours.
- the conditions for the reduction reaction are: in a hydrogen atmosphere, the reaction is carried out at 35°C to 50°C for 40 hours to 50 hours.
- step (b) the compound of formula 5 is purified, and the purification operation can be carried out by a conventional method in the art.
- the synthesis steps and reaction conditions of the compound of formula 5m are as described in the synthesis method of the compound of formula 5 above, with the difference that the compound of formula 4 is replaced with the compound of formula 4m.
- the method for synthesizing the compound of formula 6 is step (c): in an organic solvent, the compound of formula 5 is ring-closed under the action of an acid to obtain the compound of formula 6
- the acid is selected from one or more of trifluoroacetic acid, methanesulfonic acid, p-toluenesulfonic acid, formic acid, acetic acid, and hydrochloric acid.
- the organic solvent is selected from at least one of dichloromethane, methanol, ethanol, and isopropanol.
- the acid is selected from trifluoroacetic acid
- the organic solvent is isopropanol
- step (c) the amount ratio of the compound of formula 5 to the acid substance is 1: (1.5 to 2).
- step (c) is specifically: the compound of formula 5 is reacted in isopropanol under reflux under the action of trifluoroacetic acid for 1 hour to 3 hours; for example, the reaction time is 1.5 hours to 3 hours.
- the compound of formula 6 is purified, that is, the reaction solution is suction filtered, the filter cake is rinsed with isopropanol, and dried to obtain a purified compound of formula 6.
- the synthesis steps and reaction conditions of the compound of formula 6m are as described in the synthesis method of the compound of formula 6 above, with the difference that the compound of formula 5 is replaced with the compound of formula 5m.
- the method for synthesizing the compound of formula 7 is step (d): in an organic solvent, the amino protecting group of the compound of formula 6 is removed to obtain the anti-tumor compound of formula 7.
- the organic solvent is selected from one or more of toluene, dichloromethane, acetonitrile, tetrahydrofuran, methanol, ethanol, and isopropanol.
- the organic solvent is toluene.
- a catalyst may also be added, and the catalyst is selected from at least one of formic acid, acetic acid, hydrochloric acid, methanesulfonic acid, and trifluoroacetic acid.
- the catalyst is selected from trifluoroacetic acid.
- step (d) alcohol or phenol is also added, the alcohol is selected from methanol and/or ethanol; the phenol is selected from phenol and/or p-methoxyphenol. Further, for example, the addition amount of alcohol or phenol is 1 to 2 molar equivalents of the compound of formula 6.
- step (d) the compound of formula 7 is purified, and the purification operation can be carried out by a conventional method in the art.
- the synthesis steps and reaction conditions of replacing the compound of formula 6 with the compound of formula 6m to synthesize the compound of formula 7 are as described in the synthesis method of the compound of formula 7 above.
- the compound of formula 7 can also be directly synthesized by a compound of formula 5M in one step.
- the reaction conditions are: in an organic solvent, the compound of formula 5M is reacted under the action of an acid to obtain the compound of formula 7.
- an acid for example, under the action of trifluoroacetic acid, reflux reaction for 20-40 hours.
- the organic solvent is selected from one or more of toluene, dichloromethane, acetonitrile, 2-methyltetrahydrofuran, tetrahydrofuran, methanol, ethanol and isopropanol.
- the method for synthesizing the anti-tumor compound of Formula 7 further includes the step of synthesizing the compound of Formula 2M:
- the amino protecting reagent is Boc 2 O, CbzCl, TosCl, FmocCl, PMBBr, MOMCl, EOMCl, tert-butanol, isobutylene, BnCl, acetic anhydride, SEMCl, TrtCl or DHP, such as Boc 2 O, CbzCl, TosCl, FmocCl, PMBBr, TrtCl or DHP; P 1 is selected from Boc, Cbz, Tos, Fmoc, PMB, MOM, EOM, tBu, Bn, Ac, SEM, Trt or THP, such as Boc, Cbz, Tos, Fmoc, PMB, Trt or THP ; P 1 is connected to any N atom on the ring, preferably P 1 is connected to the N atom ortho to the methyl group on the ring.
- the amino protecting reagent is TrtCl or DHP; P 1 is selected from TrtCl or DHP
- the compound of formula (2-3)M includes the following compound of formula 2-3 and compound of formula (2-3)m:
- the solvent in step (i) is concentrated sulfuric acid, acetic anhydride, acetic acid;
- the conditions for the nitration reaction in step (i) are: in concentrated sulfuric acid at 10°C to 20°C for 0.5 hour to 2 hours. .
- the mass-volume ratio of the compound of formula 2-1 to concentrated sulfuric acid is 100 g: (150 to 250) ml.
- the obtained compound of formula 2-2 is easy to filter, and has good solubility in solvents such as tetrahydrofuran, dichloromethane, and acetonitrile, which makes the selection of reaction solvents more diversified.
- step (ii) sets different reaction conditions according to the nature of the amino-protecting reagent.
- the reaction conditions of step (ii) are: under the action of a base, the reaction is carried out at 60°C to 100°C for 1 hour to 48 hours; when the amino-protecting reagent is DHP, the reaction conditions of step (ii) The reaction conditions are: under the action of p-toluenesulfonic acid or pyridine p-toluenesulfonate, reflux reaction at 60°C to 100°C for 3 hours to 48 hours.
- the organic solvent in step (ii) is selected from one or more of tetrahydrofuran, 2-methyltetrahydrofuran, dichloromethane and acetonitrile.
- step (ii) when the amino-protecting reagent is TrtCl, the reaction conditions of step (ii) are: under the catalysis of triethylamine, the reaction is refluxed in acetonitrile for 1 hour to 3 hours.
- the reaction conditions for removing the phthaloyl group in step (iii) are: under the action of hydrazine hydrate, reflux reaction in an organic solvent for 1 hour to 3 hours, and the organic solvent is selected from ethanol, tetrahydrofuran and acetonitrile. One or more of them.
- the method for synthesizing the anti-tumor compound of Formula 7 further includes the step of synthesizing the compound of Formula 1:
- the compound of formula 1-1 is reacted with the compound of formula 1-2 to obtain the compound of formula 1;
- X 1 , X 2 and X 3 are each selected from halogen.
- X 1 , X 2 and X 3 are each selected from chlorine.
- the conditions for the coupling reaction between the compound of formula 1-1 and the compound of formula 1-2 are: under the action of iron acetylacetonate, the reaction is carried out at -70 to -60°C.
- the present invention also provides an intermediate for preparing the anti-tumor compound of Formula 7, which has the following structural formula:
- the intermediate has the following structure:
- X 1 and X 2 are each selected from halogen
- P 1 is selected from Trt or THPP 1 and is connected to any N atom on the ring, preferably P 1 is connected to the N atom ortho to the methyl group on the ring.
- the present invention also provides an intermediate for preparing the anti-tumor compound of Formula 7, which is characterized in that it has the following structural formula:
- P 1 is selected from Trt or THP;
- the formula 6M is a complex containing 1 molecule of trifluoroacetic acid and 1 molecule of isopropanol.
- the raw materials used in the embodiments of the present invention are all commercially available products, and the purity is chemically pure.
- reaction temperature of the microreactor to -70 to -60°C, and combine the THF solution of (2-chlorophenyl)magnesium chloride and the THF solution of 4,6-dichloronicotinyl chloride through the reaction of the microreactor to obtain (2-chloro Phenyl) (4,6-dichloropyridin-3-yl)methanone reaction solution, the reaction solution is introduced into the prepared diluted hydrochloric acid for quenching. Separate the liquids to obtain a clear yellow organic phase, which is concentrated.
- Anhydrous tetrahydrofuran (500mL) and 2,5-dibromopyridine (100.0g, 0.42mol, 1.0eq) were added to a 2L four-necked flask, cooled to 2°C in an ice-water bath with stirring, and isopropylmagnesium chloride (210.5mL) ,2.0M,0.42mol,1.0eq), control the temperature not to exceed 10°C, and finish dripping in about 0.5h.
- the aqueous phase was extracted with ethyl acetate (1.0L ⁇ 2), combined with the yellow oil obtained above, washed with water (500mL), washed with saturated brine (500mL), dried over anhydrous Na 2 SO 4 , and concentrated to obtain a brown oil ( 140g crude product).
- Extract with ethyl acetate (1.0L ⁇ 2), combine all the organic phases, wash with water (800mL), saturated brine (800mL), dry with anhydrous Na 2 SO 4 , and concentrate to obtain a yellow solid, which is washed with methyl tert-butyl ether ( 500 mL)/petroleum ether (500 mL) was slurried, and a yellow solid (30 g, yield: 41.8%) was obtained after drying.
- the reaction solution was slowly poured into 36 kg of ice water, filtered with suction, and then the filter cake was added to a 50L wide-mouth bucket after being drained, 36L of water was added, stirred for half an hour, filtered with suction, and the filter cake was rinsed with water (6L).
- the filter cake was dried to a constant weight (about 72 hours) to obtain the compound of formula 2-2 as an off-white solid (4160 g, yield: 96.7%, HPLC purity 95.5%).
- Step 1 (6-Chloro-4-((5-methyl-4-nitro-1-trityl-1H-pyrazol-3-yl)amino)pyridin-3-yl)(2-chloro Synthesis of phenyl) ketone
- Step 2 (2-Chlorophenyl)(4-((5-methyl-4-nitro-1-trityl-1H-pyrazol-3-yl)amino)-6-morpholinopyridine -3-yl) ketone synthesis
- Step 1 Formula 4" compound (2-chlorophenyl) (4-((5-methyl-4-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole- Synthesis of 3-yl)amino)-6-morpholinopyridin-3-yl ketone
- the HPLC control reaction is over and the temperature is lowered to At 20-25°C, add 2L of water, separate the liquids, concentrate the organic phase, add 1L of ethyl acetate to beat for 2-4 hours, filter, and air-dried the filter cake to obtain the compound of formula 4", 218 g of yellow solid, with a yield of 51.2%.
- Step 2 The compound of formula 7 4-(5-(2-chlorophenyl)-3-methyl-2,10-dihydropyrazole[4,3-b]pyrido[4,3-e][1 ,4]Synthesis of diazepine-8-yl)morpholine
- Step 1 Compound of formula 4'(2-chlorophenyl) (4-((5-methyl-4-nitro-1-trityl-1H-pyrazol-3-yl)amino)-6- Synthesis of morpholinopyridin-3-yl)methanone
- the HPLC control reaction ended, and the system was cooled to 15-25°C. Add 7.5L of water, separate the liquids, dry the organic phase with anhydrous magnesium sulfate, filter, concentrate the filtrate to about 1-2L of solvent remaining, add 5L of toluene, 15L of ethanol, beating at 78°C for 2 hours, reduce to room temperature, filter, and dry. 1250g yellow solid, the yield is 70.3%.
- Step 2 Compound of formula 5'(4-((4-amino-5-methyl-1-trityl-1H-pyrazol-3-yl)amino)-6-morpholinopyridin-3-yl ) Synthesis of (2-chlorophenyl) ketone
- Example 1 Add water (300mL), ethanol (95%, 7.5L), ammonium chloride (30.30g, 0.57mol), iron powder (950g, 17mol) to a 20L reaction flask, stir at 55-60°C for 1.5 hours, Add THF (7.5L), the compound of formula 4'(775g, 1.13mol), reflux reaction for 5 hours, add iron powder (320g, 5.66mol), reflux reaction for 15 hours, HPLC control reaction is completed.
- reaction solution was hot filtered through diatomaceous earth (1.5kg), the filter cake was rinsed with THF (3L), the filtrate was concentrated to about 5L of solvent remaining, 5L ethanol was added, and the slurry was beaten at 65°C for 3 hours, cooled to room temperature, filtered, and used for filter cake It was rinsed with 4L of ethanol and dried to obtain 590 g of yellow solid with a yield of 79.6%.
- Example 2 Put the compound of formula 4'(6.8g, 10.0mmol), THF (150mL) into the autoclave, add platinum oxide (700mg), pass in 0.5-0.8MPa hydrogen, react at 40°C for 46 hours, and detect the reaction by HPLC completely. The reaction solution was filtered, and the filtrate was concentrated to about 50 mL remaining, 100 mL of n-heptane was added dropwise under reflux, cooled to room temperature, filtered, and dried to obtain 5.5 g of yellow solid with a yield of 84.6%.
- Step 3 The compound of formula 6'4-(5-(2-chlorophenyl)-3-methyl-2-trityl-2,10-dihydropyrazole[4,3-b]pyrido[ Synthesis of 4,3-e][1,4]diazepine-8-yl)morpholine isopropanol trifluoroacetate
- Step 4 The compound of formula 7 4-(5-(2-chlorophenyl)-3-methyl-2,10-dihydropyrazole[4,3-b]pyrido[4,3-e][1 ,4]Synthesis of diazepine-8-yl)morpholine
- Step 1 Compound of formula 7 4-(5-(2-chlorophenyl)-3-methyl-2,10-dihydropyrazole[4,3-b]pyrido[4,3-e][1 ,4]Synthesis of diazepine-8-yl)morpholine
- the compound of formula 5'(1 g, 1.53 mmol) was dissolved in DCM (10 mL), and TFA (350 mg, 3.06 mmol) was added. After stirring for 2.5 hours, the system precipitated a yellow solid, heated to reflux, the system became yellowish turbid and gradually became orange-yellow and clear. Stir overnight and react for a total of 24 hours. The system is brown-black and clear. Add EA (100 mL), saturated aqueous sodium bicarbonate solution, separate the layers, concentrate the organic phase, beaten 20 ml of EA, and filter to obtain the compound of formula 7.
- step 1 of example 5 replacing 2-MeTHF with toluene to prepare a compound of formula 4'.
- step 1 of embodiment 5 The steps of this embodiment are similar to step 1 of embodiment 5, replacing 2-MeTHF with acetonitrile to prepare a compound of formula 4'.
- step 1 of embodiment 5 The steps of this embodiment are similar to step 1 of embodiment 5, replacing 2-MeTHF with tetrahydrofuran to prepare a compound of formula 4'.
- step 2 (example 2) of embodiment 5
- the platinum oxide is replaced with Pt/C
- the compound of formula 5' is prepared after the reaction, and the yield reaches more than 80%.
- step 2 (example 2) of embodiment 5
- the platinum oxide is replaced with Pd/C
- the reaction is performed to prepare a compound of formula 5'.
- step 2 (example 2) of embodiment 5, the platinum oxide is replaced with Pd(OH) 2 /C, and the compound of formula 5'is prepared after the reaction.
- step 2 (example 2) of embodiment 5, the platinum oxide is replaced with Rh/C, and the reaction is performed to prepare a compound of formula 5'.
- step 2 of embodiment 5 replacing THF (Example 2) with a mixture of THF and isopropanol, and after reaction, the compound of formula 5'is prepared.
- step 3 of embodiment 5 the trifluoroacetic acid (TFA) is replaced with p-toluenesulfonic acid, and the compound of formula 6'is prepared after the reaction.
- TFA trifluoroacetic acid
- step 3 of embodiment 5 The steps of this embodiment are similar to step 3 of embodiment 5, and trifluoroacetic acid (TFA) is replaced with methanesulfonic acid, and the compound of formula 6'is prepared after the reaction.
- TFA trifluoroacetic acid
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (11)
- 一种式7抗肿瘤化合物的合成方法,其特征在于,包括如下步骤:(a)于有机溶剂中,将式1化合物与式2M化合物在碱的作用下发生芳香亲核取代反应得到式IM化合物,式IM化合物经分离或者不经分离,与式3化合物继续发生芳香亲核取代反应,例如与式3化合物在碱性条件下继续发生芳香亲核取代反应,得到式4M化合物;(b)于有机溶剂中,将所述式4M化合物在催化剂的作用下发生还原反应,得到式5M化合物;(c)于有机溶剂中,将所述式5M化合物在酸的作用下关环,得到式6M化合物;(d)于有机溶剂中,将所述式6M化合物脱去氨基保护基,得到式7抗肿瘤化合物;反应式如下:其中,X 1和X 2分别选自卤素;P 1为氨基保护基,优选地,P 1选自Boc、Cbz、Tos、Fmoc、PMB、MOM、EOM、tBu、Bn、Ac、SEM、Trt或THP,例如Boc、 Cbz、Tos、Fmoc、PMB、Trt或THP;P 1与所在环上的任一N原子相连,优选地P 1与所在环上的甲基邻位的N原子相连。
- 根据前述权利要求中任一项的方法,其特征在于,步骤(a)中,所述有机溶剂选自2-甲基四氢呋喃、乙腈、四氢呋喃和甲苯中的一种或几种;所述碱选自氢化钠、氢氧化钠、碳酸铯、三乙烯二胺、叔丁醇钠、叔丁醇钾、双三甲基硅基胺基锂和六甲基二硅基氮烷钠中的一种或几种;任选地步骤(a)中,反应压力为0至10MPa(表压),例如常压;反应时间为1-96小时,例如17小时;反应温度可以为回流温度;特别地,在式1化合物与式2M化合物在碱的作用下发生芳香亲核取代反应中,反应时间为3-18小时,例如反应时间为3-8小时;反应温度为40℃至70℃,例如反应温度为40℃至60℃;特别地,在与式3化合物继续发生芳香亲核取代反应中,反应时间为8小时至16小时,例如,13小时至16小时;反应温度可以为回流温度;比例为:溶剂∶式1化合物∶式2M化合物∶式3化合物∶碱=0.5-60L∶0.1-11摩尔∶1摩尔∶0.3-30摩尔∶0.2-25摩尔;例如,5.8L∶1.1摩尔∶1摩尔∶3摩尔∶2.5摩尔;特别地,在式1化合物与式2M化合物在碱的作用下发生芳香亲核取代反应中加入硫酸镁,在与式3化合物继续发生芳香亲核取代反应中加入醋酸,比例为:溶剂∶式1化合物∶式2M化合物∶式3化合物∶碱∶硫酸镁∶醋酸=0.5-60L∶0.1-11摩尔∶1摩尔∶0.3-30摩尔∶0.2-25摩尔∶0.2-20摩尔∶0.1-15摩尔,例如,5.8L∶1.1摩尔∶1摩尔∶3摩尔∶2.5摩尔∶1.6摩尔∶1.5摩尔;步骤(a)中所述的碱性条件,可以以吗啉作碱,不额外加入其他碱,也可以额外加入如氢化钠、氢氧化钠、碳酸铯、三乙烯二胺、叔丁醇钠、叔丁醇钾、双三甲基硅基胺基锂和六甲基二硅基氮烷钠中的一种或几种。
- 根据前述权利要求中任一项的方法,其特征在于,步骤(b)中,所述有机溶剂选自甲醇、乙醇、异丙醇、四氢呋喃、2-甲基四氢呋喃、醋酸和乙腈中一种或几种;所述催化剂选自铁粉、氧化铂、Pt/C、Pd(OH) 2/C、Rh/C或Pd/C;任选地步骤(b)中,当催化剂为铁粉时,反应时间为1-96小时,例如15-24小时;反应压力为0至10MPa(表压),例如常压;反应温度为回流温度;比例为:有机溶剂∶式4M化合物∶催化剂=1-130L∶1摩尔∶1至150摩尔,例如13L∶1摩尔∶10-18摩尔,例如13L∶1摩尔∶14-18摩尔,例如13L∶1摩尔∶15摩尔;特别地,当催化剂为铁粉时:步骤(b)中还加入数量为0.05-5摩尔当量,例如0.5摩尔当量的氯化铵;溶剂为乙醇与四氢呋喃的混合溶剂,例如,乙醇与四氢呋喃的体积比为(6至10)∶10;特别地,步骤(b)中,当催化剂为氧化铂、Pt/C、Pd(OH) 2/C、Rh/C或Pd/C时,反应在氢气气氛下在30℃至80℃下进行20小时至80小时;例如,反应在氢气气氛下在60℃至80℃下进行20小时至72小时;反应压力为大于0至10MPa(表压),例如0.5-2MPa;比例为溶剂∶式4M化合物∶催化剂=1-50mL∶1克∶0.03至0.2克,例如22mL∶1克∶0.1克;任选地步骤(b)中,步骤(b)中还加入少量的水,例如,水与四氢呋喃的体积比为(0.2至2)∶10。
- 根据前述权利要求中任一项的方法,其特征在于,步骤(c)中,所述酸选自三氟乙酸、甲磺酸、对甲苯磺酸、甲酸、乙酸和盐酸中的一种或几种;所述有机溶剂选自二氯甲烷、甲醇、乙醇和异丙醇中的至少一种;任选地步骤(c)中,反应时间为1-96小时,例如1.5-3小时;反应压力为0至10MPa(表压),例如常压;反应温度为回流温度;比例为溶剂∶式5M化合物∶酸=0.5-70L∶1摩尔∶0.220摩尔,例如6.6L∶1摩尔∶2摩尔。
- 根据前述权利要求中任一项的方法,其特征在于,步骤(c)具体为:式5M化合物于异丙醇中,在三氟乙酸的作用下回流反应1小时至3小时。
- 根据前述权利要求中任一项的方法,其特征在于,步骤(d)中,所述有机溶剂选自甲苯、二氯甲烷、乙腈、四氢呋喃、甲醇、乙醇和异丙醇中的一种或几种;步骤(d)中,还加入酸,所述酸选自甲酸、乙酸、盐酸、甲磺酸和三氟乙酸中的至少一种;步骤(d)中,还加入除溶剂以外的醇或酚;所述醇选自甲醇和/或乙醇,所述酚选自苯酚和/或对甲氧基苯酚;任选地步骤(d)中,反应时间为1-96小时,例如17小时;反应压力为0至10MPa(表压),例如常压;反应温度为回流温度;比例为溶剂∶式6M化合物∶酸∶醇或酚=10-800L∶1摩尔∶0.1至10摩尔∶0.2至20摩尔,例如84L∶1摩尔∶1摩尔∶2摩尔。
- 根据前述权利要求中任一项的方法,其特征在于,还包括合成式2M化 合物的步骤:(i)于溶剂中,如浓硫酸、醋酸酐、醋酸中,将式2-1化合物(例如,1摩尔当量)与硝酸(例如,1-2摩尔当量)发生硝化反应(反应时间:0.5-2小时,反应温度;10-20℃),得到式2-2化合物;(ii)于有机溶剂如四氢呋喃、2-甲基四氢呋喃、二氯甲烷和乙腈中的一种或几种中,将所述式2-2化合物(例如,1摩尔当量)与氨基保护试剂(例如1-1.5摩尔当量)发生氨基保护反应(反应时间1-48小时,反应温度60-100℃),得到式(2-3)M化合物;(iii)于有机溶剂如乙醇、四氢呋喃和乙腈中的一种或几种中,将所述式(2-3)M化合物(例如,1摩尔当量)脱去邻苯二甲酰基(例如,反应时间:1-3小时,反应温度:回流温度),得到式2M化合物;反应式如下:其中,所述氨基保护试剂为Boc 2O、CbzCl、TosCl、FmocCl、PMBBr、MOMCl、EOMCl、叔丁醇、异丁烯、BnCl、乙酸酐、SEMCl、TrtCl或DHP,例如Boc 2O、CbzCl、TosCl、FmocCl、PMBBr、TrtCl或DHP;P 1选自Boc、Cbz、Tos、Fmoc、PMB、MOM、EOM、tBu、Bn、Ac、SEM、Trt或THP,例如Boc、Cbz、Tos、Fmoc、PMB、Trt或THP;P 1与所在环上的任一N原子相连,优选地P 1与所在环上的甲基邻位的N原子相连。
- 根据权利要求7的方法,其特征在于,当所述氨基保护试剂为TrtCl,步骤(ii)的反应条件为:在碱的作用下,60℃至100℃下反应1小时至48小时;当所述氨基保护试剂为DHP,步骤(ii)的反应条件为:在对甲苯磺酸或吡啶对甲苯磺酸盐的作用下,60℃至100℃下回流反应3小时至48小时。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/998,231 US20230212167A1 (en) | 2020-05-08 | 2021-05-08 | Method for synthesizing anti-tumor compound and intermediates thereof |
CA3182501A CA3182501A1 (en) | 2020-05-08 | 2021-05-08 | Method for synthesizing anti-tumor compound and intermediates thereof |
EP21799504.2A EP4148054A4 (en) | 2020-05-08 | 2021-05-08 | SYNTHESIS PROCESS FOR ANTI-TUMOOR COMPOUND AND INTERMEDIATE PRODUCT THEREOF |
KR1020227042684A KR20230008792A (ko) | 2020-05-08 | 2021-05-08 | 항종양 화합물의 합성방법 및 그 중간체 |
JP2022567697A JP2023525732A (ja) | 2020-05-08 | 2021-05-08 | 抗腫瘍化合物の合成方法及びその中間体 |
BR112022022477A BR112022022477A2 (pt) | 2020-05-08 | 2021-05-08 | Método para sintetizar composto antitumoral e intermediários do mesmo |
AU2021267622A AU2021267622A1 (en) | 2020-05-08 | 2021-05-08 | Synthesis method for anti-tumor compound and intermediate thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010390390.3 | 2020-05-08 | ||
CN202010390390 | 2020-05-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021223751A1 true WO2021223751A1 (zh) | 2021-11-11 |
Family
ID=78378008
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/092315 WO2021223751A1 (zh) | 2020-05-08 | 2021-05-08 | 抗肿瘤化合物的合成方法及其中间体 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230212167A1 (zh) |
EP (1) | EP4148054A4 (zh) |
JP (1) | JP2023525732A (zh) |
KR (1) | KR20230008792A (zh) |
CN (1) | CN113620949A (zh) |
AU (1) | AU2021267622A1 (zh) |
BR (1) | BR112022022477A2 (zh) |
CA (1) | CA3182501A1 (zh) |
TW (1) | TW202144360A (zh) |
WO (1) | WO2021223751A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202302114A (zh) * | 2021-03-29 | 2023-01-16 | 大陸商藥捷安康(南京)科技股份有限公司 | 多激酶抑制劑的聯合應用 |
CA3240101A1 (en) * | 2021-11-27 | 2023-06-01 | Transthera Sciences (Nanjing), Inc. | Novel use of kinase inhibitor |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1348455A (zh) * | 1999-04-21 | 2002-05-08 | 霍夫曼-拉罗奇有限公司 | 作为cdk2抑制剂的吡唑并苯并二氮䓬 |
WO2018108079A1 (zh) | 2016-12-13 | 2018-06-21 | 南京药捷安康生物科技有限公司 | 多激酶抑制剂化合物、其晶型及用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102603743B (zh) * | 2012-02-24 | 2014-05-28 | 南京天易生物科技有限公司 | 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途 |
-
2021
- 2021-05-08 EP EP21799504.2A patent/EP4148054A4/en active Pending
- 2021-05-08 AU AU2021267622A patent/AU2021267622A1/en active Pending
- 2021-05-08 US US17/998,231 patent/US20230212167A1/en active Pending
- 2021-05-08 TW TW110116666A patent/TW202144360A/zh unknown
- 2021-05-08 BR BR112022022477A patent/BR112022022477A2/pt unknown
- 2021-05-08 CN CN202110499864.2A patent/CN113620949A/zh active Pending
- 2021-05-08 CA CA3182501A patent/CA3182501A1/en active Pending
- 2021-05-08 JP JP2022567697A patent/JP2023525732A/ja active Pending
- 2021-05-08 WO PCT/CN2021/092315 patent/WO2021223751A1/zh unknown
- 2021-05-08 KR KR1020227042684A patent/KR20230008792A/ko active Search and Examination
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1348455A (zh) * | 1999-04-21 | 2002-05-08 | 霍夫曼-拉罗奇有限公司 | 作为cdk2抑制剂的吡唑并苯并二氮䓬 |
WO2018108079A1 (zh) | 2016-12-13 | 2018-06-21 | 南京药捷安康生物科技有限公司 | 多激酶抑制剂化合物、其晶型及用途 |
Non-Patent Citations (1)
Title |
---|
See also references of EP4148054A4 |
Also Published As
Publication number | Publication date |
---|---|
EP4148054A4 (en) | 2024-06-05 |
KR20230008792A (ko) | 2023-01-16 |
AU2021267622A1 (en) | 2022-12-15 |
US20230212167A1 (en) | 2023-07-06 |
JP2023525732A (ja) | 2023-06-19 |
EP4148054A1 (en) | 2023-03-15 |
CA3182501A1 (en) | 2021-11-11 |
TW202144360A (zh) | 2021-12-01 |
BR112022022477A2 (pt) | 2022-12-13 |
CN113620949A (zh) | 2021-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW492971B (en) | Nitrogen containing heteroaromtics as factor XA inhibitors | |
CN110536884A (zh) | Mcl-1抑制剂的合成 | |
WO2019076343A1 (zh) | Pd-1/pd-l1小分子抑制剂及其制备方法和用途 | |
WO2021223751A1 (zh) | 抗肿瘤化合物的合成方法及其中间体 | |
TW200526620A (en) | Pyrazine derivatives and pharmaceutical use thereof | |
CN105189479A (zh) | 氘代的二氨基嘧啶化合物以及包含该化合物的药物组合物 | |
JP6894917B2 (ja) | ピリジニルアミノピリミジン誘導体のメシル酸塩の結晶形、その製造方法及びその使用 | |
CN107200741B (zh) | 一种间变性淋巴瘤激酶抑制剂的制备方法 | |
CN111961034A (zh) | 用作ret激酶抑制剂的化合物及其应用 | |
WO2023005281A1 (zh) | 一种具有大环骨架结构的新型cdk9抑制剂的制备及其应用 | |
CN113666909B (zh) | 一种托匹司他的制备方法 | |
CN110606842B (zh) | 吡啶胺基嘧啶衍生物的制备方法及其中间体 | |
JP2024530956A (ja) | 多環式系化合物およびその使用 | |
CN106146518A (zh) | 一种布鲁顿酪氨酸激酶抑制剂中间体及其制备方法 | |
CN117561259A (zh) | 含氮多环稠环类化合物的制备方法及其中间体和用途 | |
TW479058B (en) | 2,7-substituted octahydro-pyrrolo[1,2-a]pyrazine derivatives | |
AU772981B2 (en) | Method for producing 4-(heteroaryl-methyl)-halogen-1(2H)-phthalazinones | |
US20150329521A1 (en) | Process for making reverse transcriptase inhibitors | |
CN109761914B (zh) | 一种制备5-三氟甲基尿嘧啶的方法 | |
JP6427695B2 (ja) | 1,2,5−チアジアゾリジン−1,1−ジオキシドの塩形態、結晶形態及びその調製方法と中間体 | |
CN107118164B (zh) | 5-氯-6-(氯甲基)-2,4-(1h,3h)-嘧啶二酮的制备方法 | |
WO2013178020A1 (zh) | 一种制备依曲韦林的方法及其中间体 | |
CN114213396B (zh) | 一种吲哚-2-酮类化合物及其制备方法与用途 | |
CN109970673B (zh) | 帕瑞昔布钠杂质的制备方法 | |
CA3054753A1 (en) | Pyridyl derivatives as bromodomain inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21799504 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022567697 Country of ref document: JP Kind code of ref document: A Ref document number: 3182501 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022022477 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20227042684 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 112022022477 Country of ref document: BR Kind code of ref document: A2 Effective date: 20221104 |
|
ENP | Entry into the national phase |
Ref document number: 2021267622 Country of ref document: AU Date of ref document: 20210508 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2021799504 Country of ref document: EP Effective date: 20221208 |